Clinical TrialJul 7, 2026, 05:17 PM
Conexeu Completes Preclinical P.R.O.O.F Study for CXU™ Platform
AI Summary
Conexeu Sciences Inc. announced the completion of its 12-month P.R.O.O.F (Performance and Regeneration Outcomes of Flowable Collagen) preclinical study for its CXU™ platform. The study demonstrated successful tissue restoration in facial and large-volume models, and met performance benchmarks for injectable aesthetics, providing an evidence base for its planned entry into the medical aesthetics market. The company aims to address a growing tissue-restoration gap, particularly driven by the GLP-1 weight-loss drug market, and plans a Q1 2027 510(k) submission in wound care as its initial regulatory step.
Key Highlights
- Conexeu completed its 12-month P.R.O.O.F preclinical study for the CXU™ platform.
- Study met objectives for tissue restoration in small-volume facial and large-volume (200cc-equivalent) models.
- CXU™ platform met performance benchmarks for injectability and volumizing for aesthetic injectables.
- GLP-1 weight-loss drug market projected to reach $190 billion by 2035.
- GLP-1 related tissue-restoration market gap expected to grow from $0.7 billion to $2.0 billion by 2030.
- Company plans a predicate-based 510(k) submission in wound care for Q1 2027.
- CXU™ platform is protected by a multi-jurisdictional patent estate in over 40 jurisdictions.
Price Impact
More from CNXU